RT Journal Article
SR Electronic
T1 Coronary artery disease and prostate cancer share a common genetic risk mediated through Lipoprotein(a)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.11.08.22282072
DO 10.1101/2022.11.08.22282072
A1 Baylis, Richard A.
A1 Wang, Fudi
A1 Gao, Hua
A1 Bell, Caitlin
A1 Luo, Lingfeng
A1 Nead, Kevin T.
A1 Neilan, Tomas G.
A1 Ross, Elsie Gyang
A1 Klarin, Derek
A1 Leeper, Nicholas J.
YR 2022
UL http://medrxiv.org/content/early/2022/11/08/2022.11.08.22282072.abstract
AB The genetics underlying cancer and cardiovascular disease have been studied for decades. However, despite sharing numerous risk factors and pathologic features, the contribution of shared genetics in these diseases remains poorly defined. Our study sought to identify common genetic factors between these two diseases. We found a unique relationship between coronary artery disease and prostate cancer that appears to be mediated through germline genetic variation in LPA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN.L. was supported by NIH R35 HL144475 and the American Heart Association EIA34770065. R.A.B. was supported by NIH F30 HL136188 K.T.N. is a Cancer Prevention Research Institute of Texas (CPRIT) Scholars in Cancer Research and is supported by CPRIT RR190077 and NCI K08CA263313. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGWAS summary statistics for 17 common cancers were obtained from the UK biobank (https://github.com/Wittelab/pancancer_pleiotropy) and for CAD from meta-analysis of UK Biobank SOFT CAD GWAS with the CARDIoGRAMplusC4D 1000 genomes-based GWAS and the Myocardial Infarction Genetics and CARDIoGRAM Exome(http://www.cardiogramplusc4d.org/). When prostate cancer was identified as the only cancer that correlated with CAD, prostate cancer GWAS summary statistics were obtained from the PRACTICAL consortium to increase the power for further analyses (http://practical.icr.ac.uk/blog/).